29

2020-10

Kintor Pharmaceutical's COVID-19 Clinical Trials for Proxalutamide to expand Patient Enrolment

Kintor Pharmaceutical Limited is delighted to announced that the clinical trial of anti-androgen treatment Proxalutamide for the novel coronavirus disease (COVID-19) has reached the initial target of 381 patients enrolment on 25 October 2020.

27

2020-10

Kintor Pharmaceutical Selected as the Excellent Case of Advanced Enterprises in 2020 Science and Technology Innovation by People.cn

Kintor Pharmaceutical has been successfully selected as the excellent case of the advanced enterprises in 2020 science and technology Innovation of the People.cn upon provision of comments and recommendations by experts.

16

2020-10

Strategic Cooperation Agreement on Biological Drug Development between Kintor Pharmaceutical and Pumis

On 16 October 2020, Kintor Pharmaceutical Limited (Stock code: 9939, “Kintor Pharmaceutical”) announced that it has entered into a strategic cooperation agreement on biological drug development with Pumis Pharmaceutical Co., Ltd (“Pumis”).

30

2020-09

Kintor Pharmaceutical Signs Strategic Cooperation Agreement with MabPlex

On 30 September 2020, Kintor Pharmaceutical Limited announced that Kintor Pharmaceutical entered into a strategic cooperation agreement with MabPlex International Ltd. , pursuant to which both parties will carry out all-round cooperation on the research and development and production in biological macromolecular drugs.

17

2020-09

Acne Drug KX-826 Gel Approved for Clinical Trials in China

On 17 September 2020, Kintor Pharmaceutical Limited is pleased to announce that it has received clinical trial approval from the National Medical Products Administration for the gel dosage form of KX-826 for the treatment of acne and androgenetic alopecia.

14

2020-09

Kintor Pharma to Apply to Launch its Prostate Cancer Drug Next Season

In an interview with the Hong Kong Economic Journal, Kintor Pharmaceutical's (09939) Chief Financial Officer Lu Yan noted that the company will submit its new drug application (NDA) for its core product GT0918 for the treatment of prostate cancer next season.

< 1...202122...28 > proceed page

Kintor